S 2172 · 115th Congress 2017โ€“2019, ended

Medical Innovation Act of 2017

Latest action · Nov 29, 2017 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedNov 29, 2017
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Medical Innovation Act of 2017

This bill amends the Public Health Service Act to require certain drug manufacturers to make payments to fund research supported by the Food and Drug Administration (FDA) and the National Institutes of Health (NIH).

A drug manufacturer with over $1 billion in net income in a fiscal year that has entered into a settlement agreement in the previous five years with a federal agency regarding specified violations must pay 0.75%-1.5% of its net income to the Department of Health and Human Services (HHS) for each of its covered blockbuster drugs. A covered blockbuster drug is a drug that has at least $1 billion in net sales in a year and was developed, in whole or in part, through federal investments in medical research, including a drug for which a patent contains information that relates to, or is based upon, federally funded research.

Each fiscal year, HHS must publish a list of manufacturers that make payments, each manufacturer's covered blockbuster drugs, and payment amounts.

Payments are divided between the FDA and the NIH in proportion to the discretionary funding of those agencies, excluding FDA user fees. Payments are not disbursed if appropriations for the FDA or the NIH are lower than in the prior fiscal year.

The FDA's priority use for payments must include advancing regulatory science for medical products.

The NIH's priority use for payments must include supporting: (1) research that fosters radical innovation, (2) research that advances fundamental knowledge and technology, (3) research related to diseases that disproportionately account for federal health care spending, and (4) early career scientists.

A covered blockbuster drug for which a manufacturer has not made a required payment is considered misbranded and may not be sold until payment is made.

Cosponsors 6

Members who signed on, in the order they did. All signed on Nov 29, 2017.

SeatCosponsorSigned on
D-MNAl FrankenOriginalNov 29, 2017
I-VTBernard SandersOriginalNov 29, 2017
D-CAKamala D. HarrisOriginalNov 29, 2017
D-NYKirsten E. GillibrandOriginalNov 29, 2017
D-OHSherrod BrownOriginalNov 29, 2017
D-WITammy BaldwinOriginalNov 29, 2017

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Nov 29, 2017

Actions 2

Everything that happened, newest first.

  1. Nov 29, 2017Introduced in Senate
  2. Nov 29, 2017Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Related bills 2

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 3163Medical Innovation Act of 2020Reintroduced BillJan 8, 2020
HR 4487Medical Innovation Act of 2017Identical billDec 1, 2017

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes.
Short Titles as Introduced
Medical Innovation Act of 2017

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Nov 29, 2017Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.